NEW YORK (GenomeWeb) – Clinical genomic testing firm MedGenome and Natera have reached an exclusive agreement to provide Natera's Panorama non-invasive prenatal test in India.

Under the terms of the agreement, MedGenome will have a license to develop the capacity of and to perform the test, which screens for trisomies, 21, 18, and 13, and certain sex chromosome abnormalities, such as monosomy X.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.